GILD Stock Analysis: Buy, Sell, or Hold?
GILD - Gilead Sciences Inc
$131.27
5.30 (4.21%)
▲
5d:
+6.0%
30d:
+2.9%
90d:
-6.44%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Distribution
None View Scanner →
Strength: 9.8/10
Get Alerted When GILD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GILD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: GILD shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$194.95
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$121.05
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GILD is currently trading at $131.27, which is considered slightly high relative to its 30-day fair value range of $124.12 to $131.29. The stock's valuation (Forward PE: 13.6) is in line with its historical norms (14.4). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This pessimistic expectation contrasts with the company's recent 54.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GILD is in a strong downtrend. The price is approaching resistance at $131.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: GILD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $157.67 (+20.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GILD is in a strong downtrend. The price is approaching resistance at $131.58. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: GILD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $157.67 (+20.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$124.12 -
$131.29
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
81.0%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 20.1% below Wall St target ($157.67)
Trading Range Analysis
30-Day Trading Range
$124.12 -
$131.29
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$122.43
Resistance Level
$131.58
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.59
Wall Street Target
$157.67
(+20.1%)
Revenue Growth (YoY)
4.4%
Earnings Growth (YoY)
54.8%
Profit Margin
31.0%
Valuation Discount vs History
-1.8% cheaper
PE vs Historical
13.6 vs 14.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.8%
(market-implied from PE analysis)
1-Year Target
$128.91
(-2%)
2-Year Target
$126.59
(-4%)
3-Year Target
$124.31
(-5%)
3-Yr Target (if PE normalizes)
(PE: 14→14)
$131.75
(+0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 17.16 | Current EPS (TTM): $7.34
Bull Case
$182.40
(+39%)
Analyst growth 31.6%, PE expands to 18.9
Base Case
$165.82
(+26%)
Market implied 31.6%, PE stable at 17.2
Bear Case
$85.66
(-35%)
Severe decline -20.0%, PE contracts to 14.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.6 to 14.4
Stabilization Target:
$139.13
(+6.0%)
PE Expansion Potential:
+6.0%
Share & Embed Analysis
Last updated: July 04, 2026 5:08 AM ET
Data refreshes hourly during market hours. Next update: 6:08 AM
Data refreshes hourly during market hours. Next update: 6:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GILD showing a specific setup today?
Insider Activity (6 Months)
2
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew D Dickinson
SELL
3000 shares
2026-04-15
Johanna Mercier
SELL
3000 shares
2026-04-15
Andrew D Dickinson
SELL
3000 shares
2026-03-16
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$130 | 62 BUY |
Advanced GILD Option Strategies
Professional options setups generated by AI based on today's GILD price and gamma walls.
